ロード中...
HRI depletion cooperates with pharmacologic inducers to elevate fetal hemoglobin and reduce sickle cell formation
Increasing fetal hemoglobin (HbF) provides clinical benefit in patients with sickle cell disease (SCD). We recently identified heme-regulated inhibitor (HRI, EIF2AK1), as a novel HbF regulator. Because HRI is an erythroid-specific protein kinase, it presents a potential target for pharmacologic inte...
保存先:
| 出版年: | Blood Adv |
|---|---|
| 主要な著者: | , , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
American Society of Hematology
2020
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7509868/ https://ncbi.nlm.nih.gov/pubmed/32956454 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020002475 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|